Last updated: August 1, 2026
Lunelle, the former U.S. brand for a monthly injectable contraceptive containing medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg, is no longer an active U.S. commercial product. The product was discontinued for commercial reasons, and no current Lunelle-specific clinical-development program or meaningful standalone market is publicly established. Its commercial position has been replaced by oral contraceptives, long-acting reversible contraceptives, progestin-only injections, transdermal systems and vaginal rings.
What is Lunelle and what drug did it contain?
Lunelle Monthly Contraceptive Injection was a combined hormonal contraceptive administered once every 28 to 30 days. Each dose contained:
| Attribute |
Lunelle |
| Active ingredients |
Medroxyprogesterone acetate and estradiol cypionate |
| Dose |
25 mg medroxyprogesterone acetate plus 5 mg estradiol cypionate |
| Route |
Intramuscular injection |
| Dosing interval |
Monthly |
| Therapeutic category |
Combined hormonal contraception |
| U.S. regulatory status |
Previously FDA approved; no current commercial U.S. availability |
| Dosage form |
Injectable suspension |
| Original commercial sponsor |
Pharmacia, later associated with Pfizer |
| Current standalone market |
No material active U.S. market |
Lunelle was designed to provide monthly suppression of ovulation with combined progestin and estrogen exposure. Its principal clinical distinction was the monthly administration schedule, compared with daily oral contraceptives and the longer dosing intervals offered by depot medroxyprogesterone acetate injections and implantable devices.
What is the FDA regulatory status of Lunelle?
Lunelle is not an active U.S. commercial contraceptive brand. Pfizer’s product information historically identified Lunelle as discontinued. The discontinuation was associated with commercial considerations rather than a publicly documented FDA safety withdrawal.
The FDA approval history matters because product discontinuation does not necessarily mean that the underlying active ingredients are unsafe or that every related formulation is prohibited. It means that the branded product is no longer marketed in the relevant jurisdiction.
FDA and Orange Book status
Lunelle does not represent an active Orange Book commercial reference product for current generic competition. Any historical patents or exclusivity periods associated with the product have expired or no longer provide a practical commercial barrier.
| Regulatory issue |
Current assessment |
| FDA approval |
Historical approval |
| Current U.S. marketing |
Discontinued |
| Current branded supply |
Not established |
| Orange Book commercial significance |
Limited or none |
| Regulatory exclusivity |
Expired |
| Generic substitution opportunity |
No active branded market to target |
| Product-specific FDA development |
No established active program |
The absence of an active marketable brand reduces the commercial value of a conventional Abbreviated New Drug Application strategy. A manufacturer would more likely pursue a new drug application, a 505(b)(2) pathway, or a different contraceptive product using a modern delivery system.
Are there active clinical trials for Lunelle?
No active Lunelle-specific clinical-development program is established in the principal public clinical-trial infrastructure. Historical studies evaluated Lunelle’s contraceptive efficacy, bleeding patterns, tolerability and hormone pharmacology, but those studies supported the original product and do not indicate current development.
Historical clinical evidence
The historical evidence base generally addressed:
- Prevention of pregnancy with monthly intramuscular administration
- Ovulation suppression
- Menstrual bleeding and spotting
- Return to fertility after discontinuation
- Estrogen- and progestin-related adverse events
- Comparison with oral contraceptive regimens
- Compliance advantages associated with monthly dosing
The product’s clinical limitations were consistent with combined hormonal contraceptives. Relevant risks included venous thromboembolism, arterial thrombotic events, hypertension, hepatic complications and estrogen-related contraindications. Monthly injection also limited rapid discontinuation compared with oral or transdermal products.
Clinical-trial outlook
| Development category |
Outlook for Lunelle |
| New efficacy trials |
Unlikely without a new sponsor |
| Pediatric studies |
No active commercial program identified |
| Postmarketing studies |
No current product-driven requirement |
| Comparative effectiveness studies |
More likely to involve newer contraceptives |
| Reformulation studies |
Possible only under a new development strategy |
| Biosimilar studies |
Not applicable |
Lunelle is a small-molecule combination product, not a biologic. Biosimilar competition is therefore irrelevant. Any successor would compete through generic, hybrid, reformulated or new-drug pathways rather than biosimilar regulation.
When did Lunelle lose exclusivity?
Lunelle’s practical exclusivity ended years ago. Its historical patents and regulatory exclusivity periods do not create a current barrier to development.
The key distinction is between legal patent expiration and commercial product discontinuation:
- The product was discontinued as a marketed brand.
- Any original composition or use patents have reached the end of their enforceable terms.
- No active branded product remains to support a conventional Paragraph IV challenge.
- A new manufacturer would still need to establish product quality, sterility, stability, manufacturing controls and clinical or pharmacokinetic comparability through the appropriate FDA pathway.
Patent and exclusivity assessment
| IP category |
Current relevance |
| Original active-ingredient patents |
Expired or commercially exhausted |
| Formulation patents |
No known active barrier with material market effect |
| Method-of-use patents |
No identified enforceable commercial barrier |
| Manufacturing patents |
Could affect a new formulation, but not the discontinued brand itself |
| Regulatory exclusivity |
Expired |
| Patent litigation |
No active Lunelle litigation of material commercial significance identified |
| Paragraph IV activity |
No current branded reference-product dispute of significance |
What patents protect Lunelle?
The historical product relied on known active pharmaceutical ingredients rather than a novel biologic platform. The likely patent estate centered on the combination, injectable formulation and contraceptive use. Those rights do not appear to provide current market exclusivity.
No current patent portfolio should be treated as a meaningful blocker to a Lunelle-like product unless a new sponsor has developed a distinct formulation, delivery device, stabilizer system, manufacturing process or dosing regimen.
What formulations could still be protected?
A modern monthly injectable using the same or related hormones could potentially seek protection for:
- Extended-release microspheres
- Reduced injection volume
- Improved suspension stability
- Lower-pain intramuscular delivery
- Subcutaneous administration
- Prefilled syringe systems
- Improved hormone-release kinetics
- Reduced estradiol exposure
- Alternative progestins
- Combination products with new excipients
Those rights would protect the new formulation or delivery platform, not the historical Lunelle product as such.
Which companies are challenging Lunelle?
No major company is publicly positioned as a current challenger to Lunelle because the branded product is no longer an active commercial target. The competitive field consists of companies selling alternative contraceptive technologies.
| Company |
Competing category |
Representative product or platform |
| Pfizer |
Combined oral contraception and other women’s health products |
Historical Lunelle sponsor; no current Lunelle commercial program |
| Viatris and other generic manufacturers |
Oral contraceptive generics |
Numerous combined and progestin-only products |
| Organon |
Long-acting and hormonal contraception |
Nexplanon and other contraceptive products |
| Bayer |
Intrauterine systems and oral contraception |
Mirena, Kyleena, Skyla and oral products |
| Pfizer and legacy Depo-Provera suppliers |
Injectable contraception |
Depot medroxyprogesterone acetate |
| Medicines360 |
Intrauterine contraception |
Liletta |
| TherapeuticsMD and other women’s-health companies |
Oral and non-oral contraception |
Alternative delivery systems |
The strongest competitive threat to a revived Lunelle product would come from long-acting reversible contraception, not from a direct monthly injectable generic. Implants and intrauterine systems provide multi-year duration and eliminate monthly adherence requirements.
How does Lunelle compare with current contraceptive alternatives?
| Product type |
Administration |
Duration |
Main commercial advantage |
| Lunelle |
Intramuscular injection |
Monthly |
Monthly non-oral dosing |
| Oral combined contraceptive |
Daily |
One day per dose |
Low cost and broad availability |
| Depot medroxyprogesterone acetate |
Injection |
About three months |
Fewer visits than monthly injection |
| Vaginal ring |
Monthly or extended schedule |
Weeks per device |
User-controlled, non-daily delivery |
| Transdermal patch |
Weekly |
One week per patch |
Less frequent than oral dosing |
| Implant |
Subdermal |
Up to several years |
High efficacy and low adherence burden |
| Intrauterine system |
Intrauterine |
Several years |
Long duration and high effectiveness |
Lunelle’s monthly schedule was less convenient than long-acting methods and less flexible than oral, patch or ring products. Its combined estrogen exposure also excluded patients with important estrogen contraindications.
What is the market projection for Lunelle?
The standalone Lunelle market projection is effectively zero in the U.S. because the brand is discontinued and there is no established active supply channel. A conventional revenue forecast would therefore overstate the commercial opportunity.
Base-case projection
| Forecast period |
Standalone Lunelle revenue outlook |
Market interpretation |
| Current period |
Negligible |
No active branded U.S. market |
| Near term |
Negligible |
No identified relaunch or clinical program |
| Three-year outlook |
Negligible absent relaunch |
Demand is captured by competing methods |
| Five-year outlook |
Highly dependent on reformulation |
A new product would be a separate asset |
A relaunch would require more than recovering the historical brand. The sponsor would need to demonstrate reliable supply, modern manufacturing controls, updated labeling, commercial differentiation and sufficient reimbursement. A new monthly injectable might obtain market share in regions where injectable contraception is accepted, but its U.S. opportunity would face established alternatives.
Commercial scenarios
| Scenario |
Probability profile |
Commercial result |
| No relaunch |
Base case |
No material Lunelle revenue |
| Brand revival using the old formulation |
Low |
Regulatory and manufacturing obstacles; weak differentiation |
| New monthly injectable using an improved formulation |
Selective opportunity |
Potentially viable if adherence, tolerability or administration improves |
| Regional licensing of a successor product |
More plausible than U.S. revival |
Market depends on local contraceptive access and reimbursement |
| Combination product with a novel delivery device |
Higher development value |
Patentable platform and differentiated pricing potential |
What generic entry risks exist?
There is no conventional generic-entry event comparable to a Paragraph IV challenge against an active, high-revenue reference product. The commercial risk is instead substitution by existing contraceptives.
A manufacturer developing a Lunelle-like product would face:
- Limited ability to rely on historical brand recognition
- Need for validated sterile injectable manufacturing
- Potentially higher clinical and regulatory costs than oral generic development
- Competition from depot injections with longer dosing intervals
- Competition from implants and intrauterine systems
- Reimbursement pressure
- Estrogen-related labeling restrictions
- Need to establish stable monthly pharmacokinetics
Manufacturing know-how may be more relevant than expired composition patents. Injectable suspension uniformity, sterility assurance, particulate control, container closure and stability could create practical barriers, even where no enforceable patent blocks market entry.
What licensing deals involve Lunelle?
No current material licensing transaction centered on Lunelle is publicly established. Historical corporate ownership and product commercialization were associated with Pharmacia and its later corporate relationships, but those arrangements do not indicate an active licensing opportunity.
A commercially relevant transaction would more likely concern:
- A new monthly contraceptive formulation
- A long-acting injectable platform
- A prefilled delivery device
- A regional contraceptive portfolio
- A reformulated estrogen-progestin combination
Key Takeaways
- Lunelle was a monthly injectable contraceptive containing medroxyprogesterone acetate and estradiol cypionate.
- The product is discontinued in the U.S. and has no established active standalone market.
- No current Lunelle-specific clinical-trial program or material patent litigation is established.
- Historical patents and regulatory exclusivity do not provide meaningful current protection.
- Biosimilar risk does not apply because Lunelle is a small-molecule combination product.
- A direct generic challenge is commercially unlikely because there is no active branded reference market.
- Any viable successor would require a new formulation, delivery system or regional market strategy.
- Long-acting reversible contraceptives are the principal competitive threat to a monthly injectable revival.
- The base-case revenue projection for the historical Lunelle product is negligible.
FAQs About Lunelle
Is Lunelle still available in the United States?
No. Lunelle is a discontinued U.S. contraceptive product and is not an established current commercial option.
Is Lunelle the same as Depo-Provera?
No. Lunelle combined medroxyprogesterone acetate with estradiol cypionate and was administered monthly. Depo-Provera contains depot medroxyprogesterone acetate and is generally administered at longer intervals.
Can a generic company launch Lunelle today?
A company could develop a similar injectable contraceptive, but it would need to satisfy FDA requirements for the selected regulatory pathway. The absence of active Lunelle exclusivity does not eliminate manufacturing, quality, clinical and regulatory requirements.
Does Lunelle have biosimilar competition?
No. Biosimilar regulation applies to biological products. Lunelle is a small-molecule hormonal combination.
Would a reformulated Lunelle product receive new patent protection?
Potentially. New patents could cover a novel formulation, delivery device, release profile, manufacturing process or administration route. Those rights would protect the new technology rather than restore exclusivity for the historical product.
References
- U.S. Food and Drug Administration. (n.d.). Lunelle Monthly Contraceptive Injection prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
- Pfizer Inc. (n.d.). Lunelle product information and discontinuation notice. Pfizer.
- ClinicalTrials.gov. (n.d.). Search results for Lunelle and medroxyprogesterone acetate plus estradiol cypionate. U.S. National Library of Medicine.
- World Health Organization. (2022). Family planning: A global handbook for providers (4th ed.). World Health Organization.
